Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Konstantinos Arnaoutakis

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Arnaoutakis, Konstantinos

Item TypeName
Grant A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients receiving Sunitinib as First-Line Therapy for Ad
Grant A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy versus Plac
Grant A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects wi
Grant A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a
Grant Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa
Grant An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunother
Grant Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of
Grant S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) (260760)
Grant A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy versus Plac
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of
Grant An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS 003) Plus Standard Treatment of Advanced Renal Cell Carcinom
Grant Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C
Grant A phase Ib/II, open-label, multictr trial w/ oral cMET inhibitor INC280 alone & combined with erlotinib vs platinum/pemetrexed in adult patients w/ EGFR mutated, cMET-amplified, locally advanced/metastatic NSCLC with acquired resistance to prior EGFR TKI
Grant S1929, Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) (273385)
Grant A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)
Grant Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients
Grant A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a
Grant A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)
Grant Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in
Grant Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C
Grant S1900G, “A Randomized Phase II Study of INC280 (capmatinib) plusOsimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplifiedStage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)”

Search Criteria
  • S Phase